Exelixis, Inc. (EXEL)
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Recs
cg690679
(< 20)
Submitted: 11/19/2009 7:03:33 PM :
Start Price:
$6.56
EXEL Score:
+2.12
long list of probables..
Recs
SierraBlue
(< 20)
Submitted: 11/17/2009 10:03:04 PM :
Start Price:
$7.10
EXEL Score:
-3.85
Telechart Pick
Recs
Recs
tonyrjohnson
(44.94)
Submitted: 11/3/2009 1:32:11 PM :
Start Price:
$6.68
EXEL Score:
-4.44
Good list of products. Good partners. good long term play
Recs
stockfreak1
(< 20)
Submitted: 10/30/2009 2:41:14 AM :
Start Price:
$5.71
EXEL Score:
-14.57
sucking afterhours.
Recs
fourthreethree
(53.50)
Submitted: 10/13/2009 1:22:31 PM :
Start Price:
$6.25
EXEL Score:
+5.51
I'm speculating that this company may have something good cooking in one of their labs and the street is apparently detecting a delectable dining experience. How horrible is that metaphor?
Recs
82882
(52.35)
Submitted: 10/6/2009 5:38:25 PM :
Start Price:
$6.35
EXEL Score:
+1.72
Baaaaaaaaaa! Baaaaaaaaaaaaa!
Recs
frtedcrilly
(32.64)
Submitted: 10/1/2009 5:21:57 PM :
Start Price:
$5.92
EXEL Score:
+6.08
like all pharma, it only takes one bad news story, one failed launch, but this companies GOOD news stories along with the regular big-pharma tie-ins should keep the balance tipped towards the (4 and 5) stars
Recs
Eudemonic
(< 20)
Submitted: 9/28/2009 7:57:00 AM :
Start Price:
$6.54
EXEL Score:
-1.77
Multiple All Star pick
Recs
bushey1
(34.46)
Submitted: 9/21/2009 11:52:42 AM :
Start Price:
$6.97
EXEL Score:
-6.51
Biotech at the molecular level is were medicine is jumping into. Nano tech is where development needs to be driven and Exelixis is leading the path.
Recs
Recs
NarGuy
(56.71)
Submitted: 7/19/2009 9:32:07 PM :
Start Price:
$4.78
EXEL Score:
+24.25
Goood pipeline, good connections, good management
Recs
runswithbulls
(55.40)
Submitted: 7/17/2009 11:28:01 PM :
Start Price:
$4.78
EXEL Score:
+24.25
EXEL has a pipeline of potential drug candidates equal to the top ten pharmaceutical companies.
Runswithbulls
Recs
MFRoadking
(89.70)
Submitted: 7/12/2009 8:05:27 AM :
Start Price:
$4.38
EXEL Score:
+28.81
I've been waiting on this one for a long time.
Recs
SmoothHughes
(42.69)
Submitted: 6/22/2009 5:29:09 AM :
Start Price:
$5.06
EXEL Score:
+11.95
Following the Fool.
Recs
SlickPilot65
(65.90)
Submitted: 6/18/2009 3:54:15 PM :
Start Price:
$5.00
EXEL Score:
+15.43
Dead money going to work
Recs
italiafool
(95.67)
Submitted: 6/15/2009 9:23:52 PM :
Start Price:
$4.95
EXEL Score:
+16.95
"Build it and they will come", or more like 'make the drugs and they will buy them'. The long term outlook from this price point is a multibagger waiting to happen.
Recs
ValueIsValuable
(97.56)
Submitted: 6/15/2009 3:44:33 PM :
Start Price:
$4.83
EXEL Score:
+19.80
Added today. Strong pipeline at compelling price.
Recs
ditto1940
(58.95)
Submitted: 5/28/2009 11:09:26 AM :
Start Price:
$5.66
EXEL Score:
-4.11
Global License agreement is positive
Recs
jbonds
(89.99)
Submitted: 5/28/2009 10:29:02 AM :
Start Price:
$9.12
EXEL Score:
-3.61
Exelixis and Sanofi-Aventis sign global license agreement for XL147 & XL765 and launch collaboration for discovery of PI3K inhibitors Sanofi-Aventis (SNY) and co announce a global license agreement for XL147 and XL765 and a collaboration for the discovery of inhibitors of phosphoinositide-3 kinase (PI3K) for the treatment of cancer. Under the license, Sanofi will have a worldwide exclusive license to XL147 and XL765, which are currently in phase 1 and phase 1b/2 clinical trials, and will have sole responsibility for all subsequent clinical, regulatory, commercial and manufacturing activities. Exelixis will participate in conducting ongoing and potential future clinical trials and manufacturing activities. Sanofi-aventis will pay Exelixis aggregate upfront cash payments of $140 mln under the license and collaboration. Exelixis will also receive guaranteed research funding of $21 mln over a three year research term under the collaboration. For the license and the collaboration, Exelixis will be eligible to receive development, regulatory and commercial milestones of over $1 bln in the aggregate, as well as royalties on sales of any products commercialized under the license or collaboration.
Exel is up over 20% on the news.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 377 1 2 3 4 5 6 7 8 9 10 Next »